Researchers reported a mechanism that enables primary effusion lymphoma cells to resist rapamycin, with hyaluronan targeting proposed as a strategy to overcome the resistance. The study points to a specific biological pathway underlying treatment failure, supporting further preclinical work and potential translational exploration for patients with refractory disease.